In pre-screening for LS, patients with absent MSH2 and/or MSH6 protein in tumor tissue constitute the most important group with germline mutations expected, since most consecutive cases lacking MLH1 and PMS2 proteins are due to acquired MLH1 promoter methylation and isolated PMS2 loss is rare [10,14]. Here, MSH6 is linked to neoplasm.